Efficacy of intracoronary nicardipine in the treatment of no-reflow during percutaneous coronary intervention

Catheterization and Cardiovascular Interventions

Volumn 68, Issue 5, 2006, Pages 671-676

  Huang, Raymond I ^a   Patel, Parul ^a   Walinsky, Paul ^a   Fischman, David L ^a   Ogilby, J David ^a   Awar, Mark ^a   Frankil, Craig ^a   Savage, Michael P ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Acute coronary syndromes; Nicardipine; No reflow; Percutaneous coronary intervention; Saphenous vein bypass graft

Indexed keywords

ANTICOAGULANT AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; NICARDIPINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; ATRIOVENTRICULAR BLOCK; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GRAFT DYSFUNCTION; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; NO REFLOW; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SAPHENOUS VEIN GRAFT; VEIN BYPASS;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CALCIUM CHANNEL BLOCKERS; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CORONARY CIRCULATION; CORONARY VESSELS; FEMALE; HUMANS; INJECTIONS, INTRA-ARTERIAL; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NICARDIPINE; RESEARCH DESIGN; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 33750891166     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.20885     Document Type: Article

References (36)

1. Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002; 105:656-662.
2. Piana RN, Paik GY, Moscucci M, et al. Incidence and treatment of no-reflow after percutaneous coronary intervention. Circulation 1994;89:2514-2518.
3. Abbo KM, Dooris M, Glazier S, et al. Features and outcome of no-reflow after percutaneous coronary intervention. Am J Cardiol 1995;75:778-782.
4. Kitazume H, Iwama T, Kubo H, et al. No-reflow phenomenon during percutaneous transluminal coronary angioplasty. Am Heart J 1988;116:211-215.
5. Resnic FS, Wainstein M, Lee MKY, et al. No-reflow is an independent predictor of death and myocardial infarction after percutaneous coronary intervention. Am Heart J 2003;145:42-46.
6. Eeckhout E, Kern MJ. The coronary no-flow phenomenon: A review of mechanisms and therapies. Eur Heart J 2001;22:729-739.
7. Paik GY, Caputo RP, Nunez BD, et al. Thrombus contains soluble factors which decrease blood flow in swine coronary arteries through a nitrous oxide-dependent pathway. J Am Coll Cardiol 1994;23:64A.
8. Sakuma T, Leong-Poi H, Fisher NG, et al. Further insights into the no-reflow phenomenon after primary angioplasty in acute myocardial infarction: The role of microthromboemboli. J Am Soc Echocardiogr 2003;16:15-21.
9. Klein LW, Kern MJ, Berger P, et al. Society of cardiac angiography and interventions: Suggested management of the no-reflow phenomenon in the cardiac catheterization laboratory. Catheter Cardiovasc Interv 2003;60:194-201.
10. Lambert CR, Pepine CJ. Nicardipine. In: Messerli FH, editor. Cardiovascular Drug Therapy. Philadelphia: W.B. Saunders; 1990. pp 979-994.
11. Lambert CR, Pepine CJ. Effects of intravenous and intracoronary nicardipine. Am J Cardiol 1989;64:8H-15H.
12. Kaufmann P, Vassalli G, Utzinger U, et al. Coronary vasomotion during dynamic exercise: Influence of intravenous and intracoronary nicardipine. J Am Coll Cardiol 1995;26:624-631.
13. Fugit MD, Rubal BJ, Donovan DJ. Effects of intracoronary nicardipine, diltiazem and verapamil on coronary blood flow. J Invasive Cardiol 2000;12:80-85.
14. Fischell TA, Maheshwari A. Current applications for nicardipine in invasive and interventional cardiology. J Invasive Cardiol 2004; 16:428-432.
15. Sheehan FH, Braunwald E, Canner P, et al. The effect of intravenous thrombolytic therapy on left ventricular function: A report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial. Circulation 1987;72:817-829.
16. Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: A quantitative method of assessing coronary artery flow. Circulation 1996;93:879-888.
17. Skelding KA, Goldstein JA, Mehta L, et al. Resolution of refractory no-reflow with intracoronary epinephrine. Catheter Cardiovasc Interv 2002;57:305-309.
18. Rawitcher D, Levin TN, Cohen I, et al. Rapid reversal of no-reflow using abciximab after coronary device intervention. Cathet Cardiovasc Diagn 1997;42:187-190.
19. Ishihara M, Sato H, Tateishi H, et al. Attenuation of the no-reflow phenomenon after coronary angioplasty for acute myocardial infarction with intracoronary papaverine. Am Heart J 1996; 132:959-963.
20. Fischell TA, Carter AJ, Foster MT, et al. Reversal of 'no-reflow' during vein graft stenting using high velocity boluses of intracoronary adenosine. Cathet Cardiovasc Diagn 1998;45:366, 367.
21. Barcin C, Denktas AE, Lennon RJ, et al. Comparison of combination therapy of adenosine and nitroprusside with adenosine alone in the treatment of angiographic no-reflow phenomenon. Catheter Cardiovasc Interv 2004;61:484-491.
22. Sdringola S, Assali A, Ghani M, et al. Adenosine use during aortocoronary vein graft interventions reverses but does not prevent the slow-reflow phenomenon. Catheter Cardiovasc Interv 2000;51:394-399.
23. Assali AR, Sdringola S, Ghani M, et al. Intracoronary adenosine administered during percutaneous intervention in acute myocardial infarction and reduction in the incidence of 'no-reflow' phenomenon. Catheter Cardiovasc Interv 2000;51:27-31.
24. Hanna GP, Yhip P, Fujise K, et al. Intracoronary adenosine administered during rotational atherectomy of complex lesions in native coronary arteries reduces the incidence of no-reflow phenomenon. Catheter Cardiovasc Interv 1999;48:275-278.
25. Taira N. Nicorandil as a hybrid between a hybrid nitrates and potassium channel activators. Am J Cardiol 1989;63:18J-24J.
26. Sakata Y, Kodama K, Ishikura F, et al. Disappearance of the 'no-reflow' phenomenon after adjunctive intracoronary administration of nicorandil in a patient with acute myocardial infarction. Jpn Circ J 1997;61:455-458.
27. Ito H, Taniyama Y, Iwakura K, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 1999;33:654-660.
28. Tsubokawa A, Ueda K, Sakamoto H, et al. Effect of intracoronary nicorandil administration on preventing no-reflow/slow flow phenomenon during rotational atherectomy. Circ J 2002;66:1119-1123.
29. Kaplan BM, Benzuly KH, Kinn JW, et al. Treatment of no-reflow in degenerated saphenous vein graft intervention: Comparison of intracoronary verapamil and nitroglycerin. Cathet Cardiovasc Diagn 1996;39:113-118.
30. Wang HJ, Lo PH, Lin JJ, et al. Treatment of slow/no-reflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction. Catheter Cardiovasc Interv 2004;63:171-176.
31. Bratkovsky S, Aasum E, Birkeland CH, et al. Measurement of coronary flow reserve in isolated hearts from mice. Acta Physiol Scand 2004;181:167-172.
32. Parham WA, Bouhasin A, Ciaramita JP, et al. Coronary hyperemic dose responses of intracoronary sodium nitroprusside. Circulation 2004;109:1236-1243.
33. Hillegass WB, Dean NA, Liao L, et al. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: Initial human clinical experience. J Am Coll Cardiol 2001;37:1335-1343.
34. Werner GS, Lang K, Kuehnert H, et al. Intracoronary verapamil for reversal of no-reflow during coronary angioplasty for acute myocardial infarction. Catheter Cardiovasc Interv 2002;57:444-451.
35. Weyrens FJ, Mooney J, Lesser J, et al. Intracoronary diltiazem for microvascular spasm after interventional therapy. Am J Cardiol 1995;75:849,850.
36. Jalinours F, Mooney JA, Mooney MR. Pretreatment with intracoronary diltiazem reduces non-Q wave myocardial infarction following directional atherectomy. J Invasive Cardiol 1997;9:270-273.